Paola Favuzza

发表

Basis for drug selectivity of plasmepsin IX and X inhibition in Plasmodium falciparum and vivax.

T. Triglia, A. Cowman, W. Tham, 2022, Structure.

AntigenCyRPA as Candidate Malaria Vaccine -Infected Mice Designates the falciparum Plasmodium Passive Immunoprotection of

G. Pluschke, H. Matile, T. Voss, 2012 .

Basis for drug selectivity of plasmepsin IX and X inhibition in Plasmodium falciparum and vivax.

T. Triglia, A. Cowman, J. McCauley, 2021, Structure.

Generation of monoclonal antibodies against native viral proteins using antigen-expressing mammalian cells for mouse immunization

A. Ruggieri, G. Pluschke, H. Matile, 2016, BMC Biotechnology.

Discovery and Characterization of Potent, Efficacious, Orally Available Antimalarial Plasmepsin X Inhibitors and Preclinical Safety Assessment of UCB7362

Richard D. Taylor, D. Goldberg, A. Cowman, 2022, Journal of medicinal chemistry.

Passive Immunoprotection of Plasmodium falciparum-Infected Mice Designates the CyRPA as Candidate Malaria Vaccine Antigen

G. Pluschke, H. Matile, T. Voss, 2012, The Journal of Immunology.

Generation of Plasmodium falciparum parasite-inhibitory antibodies by immunization with recombinantly-expressed CyRPA

R. Thoma, G. Pluschke, H. Matile, 2016, Malaria Journal.

Optimisation of 2-(N-phenyl carboxamide) triazolopyrimidine antimalarials with moderate to slow acting erythrocytic stage activity.

Danny W. Wilson, G. McFadden, A. Cowman, 2021, Bioorganic chemistry.

Cysteine-Rich Protective Antigen (CyRPA) as promising blood-stage candidate protein for inclusion in a malaria subunit vaccine

G. Pluschke, H. Matile, S. Wittlin, 2012, Malaria Journal.

Optimization of 2,3-Dihydroquinazolinone-3-carboxamides as Antimalarials Targeting PfATP4

A. Cowman, Adele M. Lehane, D. Fidock, 2023, Journal of medicinal chemistry.

Dual Plasmepsin-Targeting Antimalarial Agents Disrupt Multiple Stages of the Malaria Parasite Life Cycle

Manuel de Lera Ruiz, T. Triglia, A. Cowman, 2020, Cell host & microbe.

7-N-Substituted-3-oxadiazole Quinolones with Potent Antimalarial Activity Target the Cytochrome bc1 Complex

E. Winzeler, A. Cowman, G. V. van Dooren, 2023, ACS infectious diseases.

From reverse to structural vaccinology : profiling of CyRPA as new Plasmodium falciparum malaria vaccine candidate antigen

Paola Favuzza, 2015 .

Structure of the malaria vaccine candidate antigen CyRPA and its complex with a parasite invasion inhibitory antibody

M. Rudolph, A. Rufer, B. Gsell, 2016, eLife.

The Invention of WM382, a Highly Potent PMIX/X Dual Inhibitor toward the Treatment of Malaria.

Manuel de Lera Ruiz, A. Cowman, Zhuyan Guo, 2022, ACS medicinal chemistry letters.

Vaccination with virosomally formulated recombinant CyRPA elicits protective antibodies against Plasmodium falciparum parasites in preclinical in vitro and in vivo models.

M. Amacker, G. Pluschke, S. Fleury, 2020, NPJ vaccines.

Vaccination with virosomally formulated recombinant CyRPA elicits protective antibodies against Plasmodium falciparum parasites in preclinical in vitro and in vivo models

M. Amacker, G. Pluschke, S. Fleury, 2020, npj Vaccines.

Property activity refinement of 2-anilino 4-amino substituted quinazolines as antimalarials with fast acting asexual parasite activity.

Danny W. Wilson, A. Cowman, P. Gilson, 2021, Bioorganic chemistry.

Structure of the malaria vaccine candidate antigen CyRPA and its complex with a parasite invasion inhibitory antibody

M. Rudolph, A. Rufer, B. Gsell, 2017, eLife.